Aims: The ankle-brachial index (ABI) can be a prognostic marker for chronic kidney disease (CKD) in Western populations. Since there is little relevant evidence for Asian populations, we investigated the relationship between ABI and the risk of incident CKD in a general Japanese population.

Methods: The cohort included 5,072 participants aged 30–79 without a history of renal disease or cerebro-cardiovascular disease. Incident CKD, defined as an estimated glomerular filtration rate <60 (mL/min/1.73 m²) and/or proteinuria (≥ 1+ on urine dipstick), was compared among participants grouped according to baseline ABI: 0.90–0.99, 1.00–1.09, 1.10–1.19, 1.20–1.29, and 1.30–1.39. Hazard ratios for incident CKD were estimated using a Cox proportional hazards model, with the ABI 1.10–1.19 group serving as the reference.

Results: The CKD incidence rate (/100 person-years) was 1.80 during the mean follow-up period of 5.1 years. The CKD incidence rate was 3.04 in the ABI category 0.90–0.99, 1.58 in ABI 1.00–1.09, 1.72 in ABI 1.10–1.19, 2.01 in ABI 1.20–1.29, and 3.33 in ABI 1.30–1.39. The hazard ratios for developing CKD were 2.14 (95% confidence interval 1.16–3.92) in ABI 0.90–0.99, 1.08 (0.83–1.41) in ABI 1.00–1.09, 1.03 (0.83–1.29) in ABI 1.20–1.29, and 1.37 (0.77–2.47) in ABI 1.30–1.39, after adjusting for age, sex, systolic blood pressure, diabetes, and other confounding factors.

Conclusions: In a general Japanese population, an ABI of 0.90–0.99 was associated with an increased risk of incident CKD, independent of traditional cardiovascular risk factors.

Key words: Ankle-brachial index, Chronic kidney disease, Cohort study, Japanese
Sonoda et al.

Methods

Design and Participants
This retrospective cohort study included 8,828 Japanese individuals with no history of cerebrovascular, cardiovascular, or renal disease. The participants underwent an annual health check-up between January 2003 and December 2010 at Keijinkai Maruyama Clinic, a health check-up facility in Sapporo, Japan. After excluding individuals who were <30 or >79 years old, had an eGFR of <60 ml/min/1.73 m\(^2\), and/or had a protein reading of (1 +), (2 +) or (3 +) on a urine dipstick at baseline (Fig. 1), 7,994 participants eligible for a follow-up survey. The primary outcome, CKD development, was defined by an eGFR <60 ml/min/1.73 m\(^2\) and/or proteinuria, determined by a reading of (1 +), (2 +) or (3 +) on urine dipstick\(^1\). Participants’ annual health check-up data were followed until March 2014. Of the 7,905 participants, 5,072 were eligible for the final analysis (64.2%) after excluding those without follow-up information.

Baseline Survey
ABI was defined as the ratio of systolic blood pressure in the posterior tibial artery and/or the dorsalis pedis artery to systolic blood pressure in the brachial artery\(^5, 28, 29\). We used a validated, automated device (Form series BP-203RPE III; Omron-Colin Co., Tokyo, Japan), which measures blood pressure in the ankle and brachial arteries by the oscillometric method. Licensed clinical laboratory technologists performed all ABI measurements. Participants were asked to lay in the supine position for five minutes before ABI measurement. Brachial systolic blood pressure was collected from both arms, and the higher reading was used as a denominator to calculate ABI. The average of the right and leftABI was used in the analysis. Although the lower ABI from bilateral measurements is used to screen for peripheral artery disease in a primary setting, several studies reported a U-shape relationship between ABI and cardiovascular diseases\(^20, 24, 25, 30\). With reference to these findings, our study assessed whether both low and high ABI would predict CKD development.

Blood samples were obtained after overnight fasting. Serum creatinine was measured enzymatically (CicaLiquid S, Kanto Chemical Co., Inc., Tokyo, Japan). The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation with the coefficient for Japanese populations\(^31, 32\). The Modification of Diet in Renal Disease (MDRD) equation with the Japanese coefficient and the Japanese Society of Nephrology Chronic Kidney Disease Initiative (JSN-CKDI) equation were used for the sensitivity analysis\(^33\). Proteinuria was assessed by urine dipstick (Uriflet S, ARKRAY, Inc., Kyoto, Japan). Serum total cholesterol, high-density lipoprotein (HDL) cholesterol, fasting blood glucose,
and glycated hemoglobin (HbA1c) were also measured. Non-HDL cholesterol was calculated as total cholesterol minus HDL cholesterol. HbA1c was measured with the quality control standard defined by the Japan Diabetes Society and converted to the National Glycohemoglobin Standardization Program (NGSP) value. Diabetes was defined as a fasting glucose ≥ 126 mg/dL, HbA1c (NGSP) ≥ 6.5%, and/or use of medication for diabetes. Blood pressure was measured by trained nurses using a standard mercury sphygmomanometer after patients quietly sat for ten minutes. Body mass index was calculated as weight in kilograms divided by the square of height in meters. A self-administered questionnaire was used to obtain baseline medical history and smoking habits.

Follow-Up Survey
To identify CKD development during follow-up, serum creatinine and urine protein were repeatedly measured until the end of March 2014, as often as participants underwent annual health check-ups. If a participant withdrew from the follow-up survey at mid-study without developing CKD, follow-up was terminated at the latest survey that he/she underwent. The procedures for measuring these variables were consistent throughout the follow-up period. The same definition used to define CKD was used for exclusion at baseline (i.e., eGFR < 60 ml/min/1.73 m² and/or proteinuria, defined as a reading of (1 +), (2 +), or (3 +) on urine dipstick)1, 2).

Statistical Analysis
The participants were divided into the following five categories according to their ABI values: ABI 0.90–0.99, ABI 1.00–1.09, ABI 1.10–1.19, ABI 1.20–1.29, and ABI 1.30–1.39. No participants had ABI < 0.9 or > 1.39 after exclusion. CKD development (based on the CKD-EPI equation for eGFR calculation and urine dipstick) was compared among the five ABI categories. Participants who were lost to follow-up were treated as censored cases after their most recent survey. A Cox proportional hazards model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for developing CKD in each ABI category, with ABI 1.10–1.19 acting as the reference category. The reference group was based on the mean ABI values reported by previous studies in middle-aged-to-elderly Asian populations. The model incorporated the following variables as covariates: age (years as a continuous variable), sex (male or female), baseline eGFR (ml/min/1.73 m² as a continuous variable), body mass index (kg/m² as a continuous variable), smoking habits (current, former, or never smoker), using two dummy variables with never smoker as the reference), systolic blood pressure (mmHg as a continuous variable), serum non-HDL cholesterol (mg/dL as a continuous variable), HDL cholesterol (mg/dL as a continuous variable), and diabetic status (present or absent). A sensitivity analysis for developing CKD was conducted based on the MDRD and JSN-CKDI equations for eGFR calculation. Statistical analyses were performed using SPSS Ver 23.0 for Windows (IBM Institute, Tokyo, Japan).

Ethical Considerations
This study was approved by the institutional ethical committee of Hokkaido University Faculty of Medicine and Graduate School of Medicine (I 15-028) and Teine Keijinkai Medical Center. Individual informed consent was waived because of the retrospective nature of the study, and because all surveys had been done under the comprehensive prior consent arrangement before collecting data.

Results
Characteristics of Study Participants
Table 1 shows the 5,072 study participants’ baseline characteristics. Lower ABI values were associated with a higher proportion of women, higher levels of non-HDL cholesterol, and higher eGFR. Higher ABI values were associated with older age, higher proportion of current smoking status, higher systolic blood pressure, and higher proportion of diabetic participants.

ABI and Incident CKD
During the total follow-up of 25,827.9 person-years, 466 incident cases of CKD were identified (incidence rate 1.80 per 100 person-years). The CKD incidence rate in each ABI category per 100 person-years was 3.04 in ABI 0.90–0.99, 1.58 in ABI 1.00–1.09, 1.72 in ABI 1.10–1.19, 2.01 in ABI 1.20–1.29, and 3.33 in ABI 1.30–1.39. After adjusting potential confounding risk factors, the ABI 0.90–0.99 category had a significantly higher risk of developing CKD than the ABI 1.10–1.19 category: HR, 2.14 (95%CI 1.16–3.92) in ABI 0.90–0.99, 1.08 (95%CI 0.83–1.41) in ABI 1.00–1.09, 1.03 (95%CI 0.83–1.29) in ABI 1.20–1.29, and 1.37 (95%CI 0.77–2.47) in ABI 1.30–1.39 (Table 2). Our sensitivity analysis, using the MDRD and JSN-CKDI equations for eGFR calculation, showed comparable results.

Discussion and Conclusion
We found patients with ABI 0.90–0.99 had an approximately two-fold increased risk of developing
CKD was defined as eGFR < 60 mL/min/1.73 m² and/or proteinuria ≥ 1 on urine dipstick (reference 1, 2). GFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation with the coefficient for Japanese population (reference 32). Diabetes was defined as a fasting plasma glucose level ≥ 126 mg/dl and/or HbA1c ≥ 6.5%.

**Table 1.** Baseline characteristics of the 5072 participants without CKD, grouped according to ankle-brachial index

<table>
<thead>
<tr>
<th>Ankle-brachial index</th>
<th>Overall (n = 5072)</th>
<th>0.90–0.99 (n = 80)</th>
<th>1.00–1.09 (n = 843)</th>
<th>1.10–1.19 (n = 2864)</th>
<th>1.20–1.29 (n = 1209)</th>
<th>1.30–1.39 (n = 76)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, %</td>
<td>29.0 (1470)</td>
<td>43.8 (35)</td>
<td>45.1 (380)</td>
<td>29.6 (847)</td>
<td>16.8 (203)</td>
<td>6.6 (5)</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>50.6 ± 8.7</td>
<td>47.2 ± 10.0</td>
<td>47.8 ± 8.9</td>
<td>50.7 ± 8.5</td>
<td>52.2 ± 8.2</td>
<td>53.8 ± 7.5</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>23.7 ± 3.2</td>
<td>23.6 ± 4.9</td>
<td>23.2 ± 3.8</td>
<td>23.5 ± 3.0</td>
<td>24.3 ± 3.1</td>
<td>25.3 ± 2.8</td>
</tr>
<tr>
<td>Smoking status, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoker</td>
<td>44.1 (2237)</td>
<td>43.8 (35)</td>
<td>48.8 (411)</td>
<td>44.5 (1275)</td>
<td>40.5 (490)</td>
<td>34.2 (26)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>22.4 (1136)</td>
<td>25.0 (20)</td>
<td>17.9 (151)</td>
<td>21.5 (617)</td>
<td>26.9 (325)</td>
<td>30.3 (23)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>33.6 (1699)</td>
<td>31.3 (25)</td>
<td>33.3 (281)</td>
<td>33.9 (972)</td>
<td>32.6 (394)</td>
<td>35.5 (27)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>119.6 ± 15.9</td>
<td>116.2 ± 16.5</td>
<td>116.2 ± 15.7</td>
<td>119.3 ± 15.6</td>
<td>122.2 ± 16.1</td>
<td>125.8 ± 14.4</td>
</tr>
<tr>
<td>Non-HDL cholesterol (mg/dl)</td>
<td>152.0 ± 34.5</td>
<td>159.0 ± 43.6</td>
<td>151.5 ± 36.9</td>
<td>152.8 ± 34.3</td>
<td>150.1 ± 32.4</td>
<td>146.7 ± 32.4</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>5.1 (261)</td>
<td>6.3 (5)</td>
<td>4.4 (37)</td>
<td>5.3 (151)</td>
<td>4.9 (59)</td>
<td>11.8 (9)</td>
</tr>
<tr>
<td>eGFR (ml/min/1.73 m²)</td>
<td>84.5 ± 8.2</td>
<td>87.5 ± 8.1</td>
<td>86.8 ± 8.4</td>
<td>84.3 ± 8.1</td>
<td>83.4 ± 7.8</td>
<td>81.4 ± 8.5</td>
</tr>
</tbody>
</table>

Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein.

Data are presented as mean ± standard deviation for continuous variables and % (number) for categorical variables.

P values were calculated by one-way analysis of variance for continuous variables and Chi-Square test for categorical variables.

CKD was defined as eGFR < 60 mL/min/1.73 m² and/or proteinuria ≥ 1 on urine dipstick (reference 1, 2).

GFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation with the coefficient for Japanese population (reference 32). Diabetes was defined as a fasting plasma glucose level ≥ 126 mg/dl and/or HbA1c ≥ 6.5%.

**Table 2.** Hazard ratio for CKD in the study participants, grouped according to ankle-brachial index at baseline

<table>
<thead>
<tr>
<th>Ankle-brachial index</th>
<th>0.90–0.99 (n = 80)</th>
<th>1.00–1.09 (n = 843)</th>
<th>1.10–1.19 (n = 2864)</th>
<th>1.20–1.29 (n = 1209)</th>
<th>1.30–1.39 (n = 76)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>11</td>
<td>70</td>
<td>253</td>
<td>120</td>
<td>12</td>
</tr>
<tr>
<td>Person-years of follow-up</td>
<td>361.6</td>
<td>4443.6</td>
<td>14700.5</td>
<td>5961.6</td>
<td>360.6</td>
</tr>
<tr>
<td>Incidence rate (/100 person-years)</td>
<td>3.04</td>
<td>1.58</td>
<td>1.72</td>
<td>2.01</td>
<td>3.33</td>
</tr>
<tr>
<td>Age and sex-adjusted HR (95% CI)</td>
<td>2.09 (1.14–3.82)</td>
<td>1.08 (0.83–1.41)</td>
<td>Reference</td>
<td>1.06 (0.85–1.31)</td>
<td>1.69 (0.94–3.01)</td>
</tr>
<tr>
<td>Multivariate-adjusted HR (95% CI)</td>
<td>2.14 (1.16–3.92)</td>
<td>1.08 (0.83–1.41)</td>
<td>Reference</td>
<td>1.03 (0.83–1.29)</td>
<td>1.37 (0.77–2.47)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio.

Multivariate-adjusted model included the following covariates: age, sex, body mass index, smoking status, systolic blood pressure, non-high-density lipoprotein cholesterol, diabetes status, and baseline eGFR.

CKD was defined as eGFR < 60 mL/min/1.73 m² and/or proteinuria ≥ 1 on urine dipstick (reference 1, 2).

GFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation with the coefficient for Japanese population (reference 32).

CKD than patients with ABI 1.10–1.19, independent of age, sex, and potential confounding factors, including smoking, obesity, hypertension, diabetes, dyslipidemia, and baseline eGFR. To the best of our knowledge, our study is the first to demonstrate that low ABI independently predicts CKD development in a general Asian population.

Only two relevant cohort studies in Western countries have investigated the association between ABI and kidney function in a general population. O’Hare et al. observed that patients with ABI < 0.9 had a significantly higher risk for ≥ 50% increase in serum creatinine after a three-year follow-up period (9). Foster et al. observed that patients with ABI < 0.9 had a significantly higher risk for rapid eGFR decline, defined as ≥ 3 mL/min/1.73 m² decrease per year (7). Although these two cohort studies did not find a significant increase of CKD in patients with normal ABI, a normal ABI could still be associated with an increased risk of kidney function decline (6, 7). For example, O’Hare et al. observed an odds ratio of 1.9 (95%CI 0.97–3.8) for increased creatinine in the ABI 0.90–0.99 group compared to the ABI ≥ 1 group (6). Similarly, Foster et al. observed an odds ratio of 1.32 (95%CI 0.93–1.89) for microalbuminuria in the ABI 0.9–1.1 group compared to the ABI 1.1–1.4 group (7).
Although there were methodological differences between the studies (ABI categorization, definition of reference group, and outcome measures), the results may support our findings. ABI 0.90–0.99 has been considered normal for diagnosing peripheral artery disease. In this regard, the present study provided notable insights.

Patients with low ABI tend to not only have arterial stenosis in lower extremities, but also have a higher risk of coronary artery disease and stroke due to generalized atherosclerosis. In addition to the possible link between low ABI and generalized atherosclerosis, several studies assessing the link between kidney damage and atherosclerosis are worthy of attention. Iwakiri et al. found, in his autopsy series, that pathological findings in the renal vasculature, including an increased intima/media layer ratio in the renal artery, increased proportion of renal arteriolar hyalinization, and increased proportion of global glomerulosclerosis, were associated with increased degree of generalized atherosclerosis. Kasiske et al. also suggested that intrarenal vascular disease and glomerulosclerosis were associated with generalized atherosclerosis. Tracy et al. found that hyalinized renal arterioles were markers for severe atherosclerosis in coronary arteries. Nakamura et al. found in their autopsy study that asymptomatic plaques in common iliac arteries are associated with generalized atherosclerosis and renal failure.Taken together, these studies support our results that low ABI, even within clinically normal values, indicates generalized atherosclerosis and predicts development of renal vascular disease and CKD.

Various other mechanisms associated with an abnormal ABI may contribute to CKD, further supporting our findings. Ozkaramanli Gur et al. reported increased cytokine levels in both low and high ABI groups in patients with previous coronary artery bypass grafting. Therefore, both low and high ABI groups may have vascular damage in the kidney via circulatory cytokines. Wang et al. showed that exertional leg pain and intermittent claudication were more prevalent in patients with borderline-low ABI (0.91–0.99) and borderline-high ABI (≥1.40) compared to those with normal ABI (1.00–1.39). Therefore, using pain relief medication (e.g., nonsteroidal anti-inflammatory drug) for symptomatic, lower extremity artery disease may also affect kidney function. Furthermore, using hypertension medications (e.g., renin-angiotensin system blocking agents), which are usually more prevalent in both lower and higher ABI groups, can deteriorate renal function.

Ishida et al. reported that there is a possible J-shaped relationship between ABI and the risk of presence of proteinuria, but not low eGFR, in a Japanese cross-sectional study. These findings are consistent with our results demonstrating that the ABI 1.30–1.39 group was likely to have a higher risk of incident CKD, compared to the ABI 1.10–1.19 category. Furthermore, based on our findings, we could not definitively show that there is no link between high ABI and the development of CKD. It is possible that ABI has a U-shaped relationship with incident CKD.

In general, females have lower ABIs than males, which is consistent with our findings. We showed that the proportion of females decreased with increasing ABI at baseline. Unfortunately, our study did not include enough participants to conduct sex-specific analyses. In preliminary, sex-stratified analyses, we observed a U-shaped relationship between ABI and incident CKD among male participants (data not shown). However, we could not obtain reliable results among female participants because there were few CKD cases in the lowest and highest ABI groups.

Future studies, including a large number of participants, are warranted to elucidate the sex-specific effect of ABI on CKD development in Asian populations.

The strength of our study is that it included a large sample size and had a total follow-up period of 24,592.1 person-years with annual data. However, our study had several limitations. First, the study participants consisted solely of health checkup examinees at a single clinic; thus, caution should be exercised when generalizing our results. Additionally, of the health checkup examinees at the clinic, only those who voluntarily underwent ABI measurement were included in this study. Because these participants were likely to be concerned about health issues, there may have been a selection bias that they had healthier characteristics and, therefore, would be less likely to develop CKD in the future. Second, since they were relatively young and healthy, the original cohorts only included three participants with ABI <0.9 and one participant with ABI >1.39 at baseline. After selecting for eligible participants, all ABI levels fell between 0.9 and 1.39 (Fig. 1). Therefore, we were unable to determine such low or high ABI levels’ influence on future kidney function. Third, 36.5% (2,922) of the 7,994 participants who underwent the baseline survey were excluded from the analysis due to the lack of follow-up data. Additionally, 23.7% (1,145) of the 5,072 eligible participants dropped out during the follow-up period, with a mean follow-up of 1.7 years, but were included in the final analysis. However, baseline characteristics were similar between the participants who were excluded from the study, those who withdrew in mid-course, and those who completed the follow-up.
Furthermore, the mean follow-up period was similar across all ABI categories in the 5,072 eligible participants. Fourth, our follow-up observations were based on the results of a single measurement of serum creatinine and urinary protein at annual health check-ups. However, CKD diagnosis usually requires multiple observations made over three months or more. This may limit the accuracy of our outcome measurements. Finally, due to the lack of data on medication for hypertension, dyslipidemia, and diabetes, we were unable to include these conditions in the analysis.

In conclusion, this study found that ABI from 0.90 to 0.99 predicts CKD development, independent of traditional cardiovascular risk factors. In addition to detecting peripheral artery disease and predicting future cardiovascular events, ABI, even at clinically normal values, may be a useful marker for predicting future CKD.

Acknowledgments

The authors thank all the staff and participants for their important contributions.

Notice of Grant

None.

Conflict of Interest

None declared.

Author Contributions

H.S. was responsible for the study concept and design, collected the data, analyzed the data, and drafted the manuscript. K.N. and A.T. interpreted the results, and made critical revision of the manuscript.

References

6) O’Hare AM, Rodriguez RA, Bacchetti P. Low ankle-brachial index associated with rise in creatinine level over time: results from the atherosclerosis risk in communities study. Arch Intern Med, 2005; 165: 1481-1485
cohort: a collaborative meta-analysis. Lancet, 2010; 375: 2073-2081


35) Aboyans V, Criqui MH, McClelland RL, Allison MA, McDermott MM, Goff DC, Jr., Manolio TA. Intrinsic